Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004265145 | SCV003892567 | uncertain significance | not specified | 2023-01-18 | criteria provided, single submitter | clinical testing | The c.338G>A (p.R113Q) alteration is located in exon 2 (coding exon 1) of the FBXO39 gene. This alteration results from a G to A substitution at nucleotide position 338, causing the arginine (R) at amino acid position 113 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |